読み込み中
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
前日終値
$7.45
−$0.19 · -2.49%
市場前
$7.40
−$0.05 · -0.67%
10月13日 7:00 ET
日中の時刻はETです。市場データは遅延する場合があります。
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
日中レンジ
現在 $7.45
52週レンジ
現在 $7.45
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
61
割安
センチメント
63
強気
リスク
66
高リスク
モメンタム
25
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
日中レンジ
現在 $7.45
52週レンジ
現在 $7.45
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.63億 USD | 2.63億 USD | 7850万 USD | 1.31億 USD | 5360万 USD |
| 売上原価 | 520万 USD | — | — | — | — |
| 粗利益 | 2.57億 USD | 2.63億 USD | 7850万 USD | 1.31億 USD | 5360万 USD |
| 研究開発 | 2.83億 USD | 3.48億 USD | 3.8億 USD | 3.15億 USD | 1.8億 USD |
| 販売・一般管理 | 8940万 USD | 1.65億 USD | 1億 USD | 7960万 USD | 6160万 USD |
| 営業費用 | 3.72億 USD | 5.14億 USD | 4.8億 USD | 3.95億 USD | 2.42億 USD |
| 受取利息 | 2200万 USD | 5480万 USD | 3880万 USD | 1200万 USD | 180万 USD |
| 支払利息 | — | — | — | — | 10万 USD |
| 減価償却費と償却費 | 520万 USD | 660万 USD | 670万 USD | 820万 USD | 600万 USD |
| 営業利益 | −1.15億 USD | −2.5億 USD | −4.02億 USD | −2.63億 USD | −1.88億 USD |
| 純利益 | −8080万 USD | −1.99億 USD | −3.67億 USD | −2.83億 USD | −1.91億 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$14.17
上昇余地（90.20%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1767.03万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM1200.58万0.02%787.4億 USD0.19%$277.9-0.37%
Vanguard Extended Market ETFVXF692.84万0.01%954億 USD0.05%$233.52-0.63%
Fidelity Enhanced Small Cap ETFFESM357.07万0.05%64.1億 USD0.28%$45.24-0.48%
iShares Biotechnology ETFIBB347.16万0.03%108.2億 USD0.44%$204.26-1.08%
State Street SPDR S&P Pharmaceuticals ETFXPH344.12万0.75%4.69億 USD0.35%$64.01-0.99%
Vanguard Russell 2000 ETFVTWO314.23万0.02%180億 USD0.06%$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA233.48万0.01%217.13億 USD0.03%$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
